Targeting the Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
Abstract
Androgen Deprivation Therapy (ADT) remains the first-line treatment option for patients withadvanced metastatic prostate cancer. However, despite initial responses to ADT, the majorityof patients develop resistance to ADT and progress to castration resistant prostate cancer(CRPC). The mechanisms of resistance to ADT are poorly understood and remains an urgent unmetneed in prostate cancer research. It has been hypothesized that AR splice variants play acausal role in conferring endocrine resistance in prostate cancer. ARv7 is the mostfrequently expressed AR splice variant in CRPC and is associated with poor prognosis andresistance to ADT. The overarching goal of this study is to further delineate the role andmechanisms governing ARv7 activity in CRPC. We hypothesize that the use of AR N-terminaldisrupting inhibitors may target the ARv7 and demonstrate increased effectiveness in thetreatment of CRPC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2020
- Accession Number
- AD1106988
Entities
People
- Irene Lee
Organizations
- Dana–Farber Cancer Institute